These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29420758)

  • 21. FDA recognition of first-world drug regulators as means of relieving U.S. drug shortages.
    Hunnisett-Dritz D
    Am J Health Syst Pharm; 2012 Oct; 69(19):1626, 1628. PubMed ID: 22997113
    [No Abstract]   [Full Text] [Related]  

  • 22. An Analytic Investigation of the Drug Formulation-Based Recalls in the USA: See More Beyond the Literal.
    Yang M; Byrn SR; Clase KL
    AAPS PharmSciTech; 2020 Jul; 21(5):198. PubMed ID: 32676955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Nontrivial Analysis of Patient Safety Risk from Parenteral Drug- and Medical Device-Borne Endotoxin.
    Tidswell EC
    Drugs R D; 2023 Mar; 23(1):65-76. PubMed ID: 36829051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lesson Learnt from Recall of Valsartan and Other Angiotensin II Receptor Blocker Drugs Containing NDMA and NDEA Impurities.
    Charoo NA; Ali AA; Buha SK; Rahman Z
    AAPS PharmSciTech; 2019 Apr; 20(5):166. PubMed ID: 30989447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cleaning Validation: Complete Guide for Health - Based Approach in Chemical Cross - Contamination Risk Assessment.
    Tanyous JN
    PDA J Pharm Sci Technol; 2019; 73(2):204-210. PubMed ID: 30361288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug recalls as viewed by the wholesaler.
    Albers ES
    J Am Pharm Assoc; 1967 Nov; 7(11):579-80. PubMed ID: 6072871
    [No Abstract]   [Full Text] [Related]  

  • 27. Emerging technology: A key enabler for modernizing pharmaceutical manufacturing and advancing product quality.
    O'Connor TF; Yu LX; Lee SL
    Int J Pharm; 2016 Jul; 509(1-2):492-498. PubMed ID: 27260134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blood product recalls in the United States.
    McCullough J; Riley E; Lindgren B; Pulkrabek S; Hall R; Riley W
    Transfusion; 2014 Sep; 54(9):2276-82. PubMed ID: 24863173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Why are there so many drug shortages?
    Weaver JM
    Anesth Prog; 2010; 57(3):89-90. PubMed ID: 20843222
    [No Abstract]   [Full Text] [Related]  

  • 30. Categorization and comparisons of drug recalls for manufacturers and compounders.
    Mattingly AN; Mattingly TJ; Nguyen Phan AL; Negash K
    J Am Pharm Assoc (2003); 2022; 62(4):1344-1350. PubMed ID: 35422393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A QRM Discussion of Microbial Contamination of Non-sterile Drug Products, Using FDA and EMA Warning Letters Recorded between 2008 and 2016.
    Santos AMC; Doria MS; Meirinhos-Soares L; Almeida AJ; Menezes JC
    PDA J Pharm Sci Technol; 2018; 72(1):62-72. PubMed ID: 29242394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FDA warns of nonsterile saline solution bags.
    Cima G
    J Am Vet Med Assoc; 2015 Mar; 246(6):579-80. PubMed ID: 26027055
    [No Abstract]   [Full Text] [Related]  

  • 33. The epidemiology of drug recalls in the United States.
    Wang B; Gagne JJ; Choudhry NK
    Arch Intern Med; 2012 Jul; 172(14):1109-10. PubMed ID: 22664942
    [No Abstract]   [Full Text] [Related]  

  • 34. Here today, gone tomorrow: diagnostic and treatment challenges created by medication shortages and discontinuations.
    Burr MS
    J Pediatr Nurs; 2012 Aug; 27(4):430-2. PubMed ID: 22497743
    [No Abstract]   [Full Text] [Related]  

  • 35. Aseptic process monitoring--a better strategy. Validation Group, Inc.
    Wilson JD
    PDA J Pharm Sci Technol; 1999; 53(3):111-4. PubMed ID: 10754699
    [No Abstract]   [Full Text] [Related]  

  • 36. Report on the PQRI impurity characterization and quantification best practices survey.
    Faustino P; Chan CC; Carrano J; Gosnell M; Gu ZQ; Maule A; Sigvardson K; Zhang YF
    Pharm Res; 2006 Feb; 23(2):440-6. PubMed ID: 16477396
    [No Abstract]   [Full Text] [Related]  

  • 37. Heparin crisis 2008: a tipping point for increased FDA enforcement in the pharma sector?
    Rosania L
    Food Drug Law J; 2010; 65(3):489-501, ii. PubMed ID: 24479237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A four-year assessment of the characteristics of Rwandan FDA drug recalls.
    Bahizi M; Nyirimigabo E; Ntirenganya L; Umuhoza MI; Habyalimana V; Bikorimana G; Ukwishaka J
    BMC Public Health; 2024 Jul; 24(1):1784. PubMed ID: 38965502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Report suggests steps to improve safety of drug supply.
    Traynor K
    Am J Health Syst Pharm; 2011 Sep; 68(17):1570, 1574. PubMed ID: 21856799
    [No Abstract]   [Full Text] [Related]  

  • 40. Good validation practices: FDA issues.
    Levchuk JW
    PDA J Pharm Sci Technol; 1994; 48(5):221-3. PubMed ID: 8000894
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.